| Cancer immunotherapy efficacy and patients' sex: a systematic review and meta-analysis F Conforti, L Pala, V Bagnardi, T De Pas, M Martinetti, G Viale, RD Gelber, ... The Lancet Oncology 19 (6), 737-746, 2018 | 783 | 2018 |
| Talimogene laherparepvec (T-VEC): an intralesional cancer immunotherapy for advanced melanoma PF Ferrucci, L Pala, F Conforti, E Cocorocchio Cancers 13 (6), 1383, 2021 | 189 | 2021 |
| Sex-based heterogeneity in response to lung cancer immunotherapy: a systematic review and meta-analysis F Conforti, L Pala, V Bagnardi, G Viale, T De Pas, E Pagan, ... JNCI: Journal of the National Cancer Institute 111 (8), 772-781, 2019 | 176 | 2019 |
| Tocilizumab for patients with COVID-19 pneumonia. The single-arm TOCIVID-19 prospective trial F Perrone, MC Piccirillo, PA Ascierto, C Salvarani, R Parrella, AM Marata, ... Journal of translational medicine 18 (1), 405, 2020 | 151 | 2020 |
| Phase II study of everolimus in patients with thymoma and thymic carcinoma previously treated with cisplatin-based chemotherapy PA Zucali, T De Pas, G Palmieri, A Favaretto, A Chella, M Tiseo, M Caruso, ... Journal of Clinical Oncology 36 (4), 342-349, 2018 | 141 | 2018 |
| Effect of concomitant medications with immune-modulatory properties on the outcomes of patients with advanced cancer treated with immune checkpoint inhibitors: development and … S Buti, M Bersanelli, F Perrone, M Tiseo, M Tucci, V Adamo, LS Stucci, ... European Journal of Cancer 142, 18-28, 2021 | 92 | 2021 |
| Evaluation of pathological complete response as surrogate endpoint in neoadjuvant randomised clinical trials of early stage breast cancer: systematic review and meta-analysis F Conforti, L Pala, I Sala, C Oriecuia, T De Pas, C Specchia, R Graffeo, ... Bmj 375, 2021 | 91 | 2021 |
| Molecular pathways: anticancer activity by inhibition of nucleocytoplasmic shuttling F Conforti, Y Wang, JA Rodriguez, AT Alberobello, YW Zhang, ... Clinical Cancer Research 21 (20), 4508-4513, 2015 | 74 | 2015 |
| Androgen receptor blockade promotes response to BRAF/MEK-targeted therapy CP Vellano, MG White, MC Andrews, M Chelvanambi, RG Witt, ... Nature 606 (7915), 797-803, 2022 | 69 | 2022 |
| Thymic epithelial tumors: From biology to treatment F Conforti, L Pala, G Giaccone, T De Pas Cancer treatment reviews 86, 102014, 2020 | 65 | 2020 |
| Sex-based dimorphism of anticancer immune response and molecular mechanisms of immune evasion F Conforti, L Pala, E Pagan, V Bagnardi, T De Pas, P Queirolo, ... Clinical Cancer Research 27 (15), 4311-4324, 2021 | 60 | 2021 |
| Late immune-related adverse events in long-term responders to PD-1/PD-L1 checkpoint inhibitors: a multicentre study O Nigro, G Pinotti, F De Galitiis, FR Di Pietro, R Giusti, M Filetti, ... European Journal of Cancer 134, 19-28, 2020 | 57 | 2020 |
| PI3K as a potential therapeutic target in thymic epithelial tumors AT Alberobello, Y Wang, FJ Beerkens, F Conforti, JN McCutcheon, G Rao, ... Journal of Thoracic Oncology 11 (8), 1345-1356, 2016 | 57 | 2016 |
| Sex-based differences in response to anti-PD-1 or PD-L1 treatment in patients with non-small-cell lung cancer expressing high PD-L1 levels. A systematic review and meta … F Conforti, L Pala, E Pagan, C Corti, V Bagnardi, P Queirolo, C Catania, ... ESMO open 6 (5), 100251, 2021 | 52 | 2021 |
| EGFR tyrosine kinase inhibitors beyond focal progression obtain a prolonged disease control in patients with advanced adenocarcinoma of the lung F Conforti, C Catania, F Toffalorio, M Duca, G Spitaleri, M Barberis, ... Lung Cancer 81 (3), 440-444, 2013 | 51 | 2013 |
| Metaplastic breast cancer: prognostic and therapeutic considerations G Corso, S Frassoni, A Girardi, E De Camilli, E Montagna, M Intra, ... Journal of Surgical Oncology 123 (1), 61-70, 2021 | 44 | 2021 |
| Moderate penetrance genes complicate genetic testing for breast cancer diagnosis: ATM, CHEK2, BARD1 and RAD51D R Graffeo, HQ Rana, F Conforti, B Bonanni, MJ Cardoso, ... The Breast 65, 32-40, 2022 | 43 | 2022 |
| Targeting ALK in patients with advanced non small cell lung cancer: biology, diagnostic and therapeutic options C Lazzari, G Spitaleri, C Catania, M Barberis, C Noberasco, M Santarpia, ... Critical reviews in oncology/hematology 89 (3), 358-365, 2014 | 43 | 2014 |
| Therapeutic effects of XPO1 inhibition in thymic epithelial tumors F Conforti, X Zhang, G Rao, T De Pas, Y Yonemori, JA Rodriguez, ... Cancer research 77 (20), 5614-5627, 2017 | 42 | 2017 |
| Palliative sedation in terminal cancer patients admitted to hospice or home care programs: does the setting matter? Results from a national multicenter observational study A Caraceni, R Speranza, E Spoldi, CS Ambroset, S Canestrari, M Marinari, ... Journal of pain and symptom management 56 (1), 33-43, 2018 | 41 | 2018 |
